Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Key Points

• Alkermes updated its FY 2025 earnings guidance, projecting EPS between 1.030 and 1.210 and revenue of $1.3 billion to $1.4 billion, both below consensus estimates.
• Recent analyst reports show a mix of ratings, with several firms affirming a "buy" rating and price targets ranging from $40.92 to $45.00.
• Alkermes reported a 12.6% year-over-year decline in revenue for its last quarter, with an EPS of $0.13 that fell short of the consensus estimate of $0.32.

Alkermes (NASDAQ:ALKS - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.030-1.210 for the period, compared to the consensus earnings per share estimate of 1.760. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Stock Performance

Shares of NASDAQ:ALKS traded up $0.06 during trading on Friday, hitting $26.55. The company's stock had a trading volume of 1,587,001 shares, compared to its average volume of 1,802,826. Alkermes has a fifty-two week low of $25.56 and a fifty-two week high of $36.45. The stock's 50-day moving average price is $29.27 and its two-hundred day moving average price is $30.78. The company has a market capitalization of $4.38 billion, a PE ratio of 12.76, a PEG ratio of 1.71 and a beta of 0.44.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.42 by $0.10. The business had revenue of $390.66 million for the quarter, compared to analysts' expectations of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%. The company's revenue was down 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.16 earnings per share. On average, equities analysts predict that Alkermes will post 1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ALKS shares. Cantor Fitzgerald raised Alkermes to a "strong-buy" rating in a report on Tuesday, May 13th. Royal Bank Of Canada boosted their price objective on Alkermes from $40.00 to $42.00 and gave the company a "sector perform" rating in a report on Wednesday. The Goldman Sachs Group began coverage on Alkermes in a research note on Tuesday, July 15th. They issued a "buy" rating and a $43.00 target price for the company. HC Wainwright restated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research note on Monday, July 21st. Finally, UBS Group upgraded Alkermes from a "neutral" rating to a "buy" rating and lifted their target price for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Alkermes currently has an average rating of "Moderate Buy" and an average price target of $41.08.

Insider Buying and Selling

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president owned 86,208 shares of the company's stock, valued at approximately $2,680,206.72. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Alkermes by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock valued at $15,927,000 after buying an additional 20,091 shares in the last quarter. Royal Bank of Canada raised its stake in Alkermes by 117.2% during the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock valued at $9,098,000 after purchasing an additional 148,696 shares during the period. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in Alkermes during the 1st quarter valued at $213,000. Institutional investors own 95.21% of the company's stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.